296 related articles for article (PubMed ID: 31652944)
1. Anticoagulants and Osteoporosis.
Signorelli SS; Scuto S; Marino E; Giusti M; Xourafa A; Gaudio A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652944
[TBL] [Abstract][Full Text] [Related]
2. [Anticoagulants and osteoporosis].
Ferrière K; Rizzoli R
Rev Med Suisse; 2007 Jun; 3(115):1508-11. PubMed ID: 17682793
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
4. Effect of antithrombotic drugs on bone health.
Dadwal G; Schulte-Huxel T; Kolb G
Z Gerontol Geriatr; 2020 Aug; 53(5):457-462. PubMed ID: 31414167
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.
Wawrzyńska L; Tomkowski WZ; Przedlacki J; Hajduk B; Torbicki A
Pathophysiol Haemost Thromb; 2003; 33(2):64-7. PubMed ID: 14624046
[TBL] [Abstract][Full Text] [Related]
6. Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density.
Galambosi P; Hiilesmaa V; Ulander VM; Laitinen L; Tiitinen A; Kaaja R
Thromb Res; 2016 Jul; 143():122-6. PubMed ID: 27236710
[TBL] [Abstract][Full Text] [Related]
7. [Secondary osteoporosis induced by anticoagulants?].
Riess H; Loew A; Himmelreich G
Orthopade; 2001 Jul; 30(7):451-5. PubMed ID: 11515183
[TBL] [Abstract][Full Text] [Related]
8. Bone health and osteoporosis: the role of vitamin K and potential antagonism by anticoagulants.
Pearson DA
Nutr Clin Pract; 2007 Oct; 22(5):517-44. PubMed ID: 17906277
[TBL] [Abstract][Full Text] [Related]
9. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
10. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
Vedovati MC; Giustozzi M; Bonitta G; Agnelli G; Becattini C
Thromb Res; 2018 Oct; 170():175-180. PubMed ID: 30196195
[TBL] [Abstract][Full Text] [Related]
12. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
13. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
15. [Secondary anticoagulant prophylaxis with low molecular heparins or oral anticoagulants and bone mineral density].
Wawrzyńska L; Przedlacki J; Hajduk B; Tomkowski W; Fijałkowska A; Ostrowski K; Torbicki A
Pol Arch Med Wewn; 2000 Nov; 104(5):769-77. PubMed ID: 11434089
[TBL] [Abstract][Full Text] [Related]
16. Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review.
Fiore M; Maraolo AE; Chiodini P; Cerchione C; Gentile I; Borgia G; Pace MC
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):105-110. PubMed ID: 28676032
[TBL] [Abstract][Full Text] [Related]
17. The effects of heparin and low molecular weight heparins on bone.
Rajgopal R; Bear M; Butcher MK; Shaughnessy SG
Thromb Res; 2008; 122(3):293-8. PubMed ID: 17716711
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
Ornstein DL; Hong-Dice YG; Papini JR
Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
[TBL] [Abstract][Full Text] [Related]
19. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
20. Safety of low molecular weight heparins in the treatment of venous thromboembolism.
Bernardi E; Prandoni P
Expert Opin Drug Saf; 2003 Jan; 2(1):87-94. PubMed ID: 12904127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
